These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 10652419)

  • 1. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
    Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
    Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
    Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
    Rosales R; López-Contreras M; Cortes RR
    J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer.
    Meschede W; Zumbach K; Braspenning J; Scheffner M; Benitez-Bribiesca L; Luande J; Gissmann L; Pawlita M
    J Clin Microbiol; 1998 Feb; 36(2):475-80. PubMed ID: 9466762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later.
    Lehtinen M; Pawlita M; Zumbach K; Lie K; Hakama M; Jellum E; Koskela P; Luostarinen T; Paavonen J; Pukkala E; Sigstad E; Thoresen S; Dillner J
    Am J Obstet Gynecol; 2003 Jan; 188(1):49-55. PubMed ID: 12548195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
    Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
    PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Booth M; Walboomers JM; Shah KV; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):341-7. PubMed ID: 8061584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.
    Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP
    J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-16-related proteins as the serologic markers in cervical neoplasia.
    Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
    Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies.
    Baay MF; Duk JM; Groenier KH; Burger MP; de Bruijn HW; Hollema H; Stolz E; Herbrink P
    Cancer Immunol Immunother; 1997 Jun; 44(4):211-5. PubMed ID: 9222279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus seropositivity and risks of head and neck cancer.
    Smith EM; Ritchie JM; Pawlita M; Rubenstein LM; Haugen TH; Turek LP; Hamsikova E
    Int J Cancer; 2007 Feb; 120(4):825-32. PubMed ID: 17131312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief report: antibody response to E6, E7, and L1 proteins of human papillomavirus 16 in an Italian population.
    Di Lonardo A; Campo MS; Venuti A; Marcante ML
    J Med Virol; 1994 Aug; 43(4):357-61. PubMed ID: 7964645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma.
    Zumbach K; Hoffmann M; Kahn T; Bosch F; Gottschlich S; Görögh T; Rudert H; Pawlita M
    Int J Cancer; 2000 Mar; 85(6):815-8. PubMed ID: 10709102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
    Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
    Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.